Results of a clinical phase I dose-escalation study of cytarabinein combination with fixed-dose vinorelbine, paclitaxel, etoposideand cisplatin for the treatment of relapsed/refractory lymphoma

References

• Diehl V. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!. J Clin Oncol 2003; 21: 583–585
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Bertino J R, Glassman J R, Hedrick E E, Hunte S, Coady-Lyons N, , et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3385
   PubMed Web of Science ®Google Scholar
• Hauke R J, Armitage J O. Treatment of non-Hodgkin lymphoma. Curr Opin Oncol 2000; 12: 412–418
   PubMed Web of Science ®Google Scholar
• Zelenetz A D, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz C H. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14(Suppl 1)I5–I10
   PubMed Web of Science ®Google Scholar
• Vose J M. Current approaches to the management of non-Hodgkin's lymphoma. Semin Oncol 1998; 25: 483–491
   PubMed Web of Science ®Google Scholar
• Laport G F, Williams S F. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 1998; 25: 503–517
   PubMed Web of Science ®Google Scholar
• Velasquez W S, McLaughlin P, Tucker S, Hagemeister F B, Swan F, Rodriguez M A, , et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, , et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Philip T, Chauvin F, Bron D, Guglielmi C, Hagenbeek A, Coiffier B, , et al. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol 1991; 2(Suppl 1)57–64
   PubMed Web of Science ®Google Scholar
• Rowinsky E K. Paclitaxel pharmacology and other tumor types. Semin Oncol 1997; 24(Suppl 19)S19-1–S19-12
   Google Scholar
• Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, , et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35–40
   PubMed Web of Science ®Google Scholar
• Conroy T. Activity of vinorelbine in gastrointestinal cancers. Crit Rev Oncol Hematol 2002; 42: 173–178
   PubMed Web of Science ®Google Scholar
• Younes A, Ayoub J P, Sarris A, North L, Pate O, McLaughlin P, , et al. Paclitaxel (Taxol) for the treatment of lymphoma. Ann Oncol 1997; 8(Suppl 1)129–131
   PubMed Web of Science ®Google Scholar
• Rule S, Tighe M, Davies S, Johnson S. Vinorelbine in the treatment of lymphoma. Hematol Oncol 1998; 16: 101–105
   PubMed Web of Science ®Google Scholar
• Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol 1998; 103: 533–535
   PubMed Web of Science ®Google Scholar
• Balzarotti M, Santoro A, Tondini C, Fornier M, Bonadonna G. Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. Ann Oncol 1996; 7: 970–972
   PubMed Web of Science ®Google Scholar
• Devizzi L, Santoro A, Bonfante V, Viviani S, Balzarini L, Valagussa P. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 1994; 5: 817–820
   PubMed Web of Science ®Google Scholar
• Devizzi L, Santoro A, Bonfante V, Viviani S, Bonadonna G. Vinorelbine: a new promising drug in Hodgkin's disease. Leuk Lymphoma 1996; 22: 409–414
   PubMed Web of Science ®Google Scholar
• Goss P, Stewart A K, Couture F, Klasa R, Gluck S, Kaizer L, , et al. Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk Lymphoma 1999; 34: 295–304
   PubMed Web of Science ®Google Scholar
• Younes A. Paclitaxel-based treatment of lymphoma. Semin Oncol 1999; 26(Suppl 2)123–128
   PubMed Web of Science ®Google Scholar
• Kahl B S, Bailey H H, Smith E P, Turman N, Smith N, Werndli J, , et al. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. Cancer Invest 2005; 23: 13–18
   PubMed Web of Science ®Google Scholar
• Burtness B A, Psyrri A, Rose M, D'Andrea E, Staugaard-Hahn C, Henderson-Bakes M, , et al. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplant 1999; 23: 311–315
   PubMed Web of Science ®Google Scholar
• Gorodetsky R, Levdansky L, Ringel I, Vexler A. Paclitaxel-induced modification of the effects of radiation and alterations in the cell cycle in normal and tumor mammalian cells. Radiat Res 1998; 150: 283–291
   PubMed Web of Science ®Google Scholar
• Ling Y H, el-Naggar A K, Priebe W, Perez-Soler R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 1996; 49: 832–841
   PubMed Web of Science ®Google Scholar
• Hamlin P A, Zelenetz A D, Kewalramani T, Qin J, Satagopan J M, Verbel D, , et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989–1996
   PubMed Web of Science ®Google Scholar
• Lonial S, Jones T W, Devine S, Winton E F, Heffner L T, Smith K J, , et al. High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma. Leuk Lymphoma 2000; 36: 497–502
   PubMed Web of Science ®Google Scholar
• Lonial S, Hicks M, Rosenthal H, Langston A, Redei I, Torre C, , et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant 2004; 10: 848–857
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, , et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. NCI Common Toxicity Criteria, version 20. 1999
   Google Scholar